🔗 Share this article

As America proceeds with sweeping adjustments to its vaccine schedules, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by casting doubt on Covid vaccines during the global health crisis and has focused upon potential fatalities after Covid vaccination in her recent time at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Schedule

Agency leaders were set to announce major revisions to the childhood immunization program earlier this month, aligning the US with Denmark’s national calendar, according to reports – a significant shift that would place the US at odds with much of the world with little proof for benefit. The planned update has been pushed back until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to speak at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting certain pediatric vaccine recommendations in the US so as to align more like Denmark's approach, a society with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – typically the purview of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Qualifications

The appointee has no apparent experience in drug development, regulation or administrative roles, which has been customary for previous heads of the CBER. She has worked at the FDA as a senior adviser to the agency head and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She lacks experience in running a sizeable institution. She is not an expert in drug approvals.”

Previous directors of the center would “be deeply familiar with regulatory frameworks and the underlying principles of medication creation”, noted Janet Woodcock. “Frankly, she doesn’t have the type of experience that former directors who headed the center have had.”

This division has an enormous range of responsibilities at the agency, she emphasized.

“The public just pays attention on the new drug program, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and all of those need to be looked after,” Dr. Woodcock explained. “The thing you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a significant management component to the job, which manages over 5,000 employees. “It is a enormous management job, if you perform it correctly,” she said.

Response and Disputed Programs

In response to concerns about Høeg’s credentials and whether this assignment signifies more teamwork among FDA leaders on immunizations, a spokesperson said that the “questions are based on incorrect presumptions”.

“This background matches the responsibilities of her job,” the official explained, citing the time Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the agency head's new fast-track approval initiative, a disputed one-day medication authorization process that reportedly worried her preceding directors. “How are these medications being selected for this fast-track system? Who takes the calls?” Dr. Howard asked. “There’s a lot of confidentiality occurring at the FDA right now.”

Overall, he stated, “the agency seems to be moving towards more relaxed regulations of most medications, aside from shots.”

Public Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a more established, if concerning, history, critics have noted. She authored a research paper using unverified crowd-sourced reports to assess the rate of heart inflammation after COVID-19 vaccination. She advised the Florida surgeon general Joseph Ladapo, who allegedly have changed statistics to suggest Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the current administration encompassed changing regulations for novel immunizations and halting “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Høeg has according to sources suggested preventing young men from receiving Covid vaccinations.

“She’s an complete true believer who commences with her conclusions and tailors the evidence to fit the data in a very disingenuous, dishonest manner,” Dr. Howard said.

Taking Control and a “Campaign of Retribution”

Dr. Høeg aligned with other dissenters, {like|